top of page


Transforming cancer care and prevention.

One of the major challenges in diagnosing hematological and solid tumor cancers is the high degree of tumor heterogeneity. Mutations that have critical clinical implications may only be present in very low levels, making detection of these mutations difficult. Detection of such mutations is especially important in hematological and solid tumor malignancies, where tumors show a great deal of heterogeneity and accurate prognosis is essential to identifying patient with more aggressive disease.


The rapid advancement of related technologies and the dramatic decrease in costs have led to next generation sequencing (NGS) to become a powerful tool for drug research and development by the pharmaceutical industry. From the study of biological mechanisms to the search for predictive biomarkers and the selection of patients selected for clinical trials, NGS is increasingly used in precision medicine applications. In addition, the recent FDA approvals of MSK-IMPACT and F1CDx represent a historic advance in the application of NGS in clinical diagnosis. Some new treatment modalities (for example, a personalized cancer vaccine) may have an even greater demand for NGS.


As the largest NGS service provider in the world, DIPLOIDE recognizes this trend and now offers our pharmaceutical clients several key clinical grade assays in our laboratory accredited by CAP in EUROPA and CLIA in the US. UU We rely on strict quality control standards to guarantee the sequencing and quality of the data. Additional trials will be added to the list as they are developed and validated. We are totally committed to helping you achieve your drug research and development goals with our unparalleled scale, efficiency, quality and price.

We must distinguish two types of genetic variants. Germline mutations (hereditary) that are present in every cell of the body and can be transmitted to the next generation. Here, genetic testing can provide early detection of a hereditary tumor predisposition and allow individualized cancer screening to reduce the risk of cancer.


Somatic mutations (acquired) occur only in the development of cancerous cells / tissues and, therefore, are not hereditary. Variants affect all genes, including those that, after mutation, will induce specific tumor behavior. The detection of genetic variants or mutation within a particular sample increases the understanding of the behavior of the tumor and, therefore, is the basis of an individualized therapy against cancer with a better evaluation of diagnosis, prognosis and therapy.

Translational and Clinical Categories


Precision medicine for solid tumors.

The comprehensive diploid precision medicine (NovoPMTM) is a genomic profile test of cancer through next-generation sequencing. This arrangement analyzes more than 500 genes for clinically important alterations. It is known that these genes in particular are relevant for the diagnosis and / or treatment of various solid tumors according to the guidelines of the Comprehensive Cancer Network (NCCN) and
World medical literature.


Identification of candidates

for PARP inhibitor.

DipFocus PARPi CDx is a NGS-based complementary diagnostic sequence (NGS) to identify patients who can benefit from PARP inhibitor therapies (PARPi) in several types of cancer. This integrated arrangement includes sample processing, sequencing, data analysis and reporting.


RNA sequencing for FFPE specimens

This arrangement applies the power NGS for the gene expression profile of typical clinical specimens.

Based on the preparation of the TruSeq RNA access library,
We provide a robust and complete transriptomic analysis of human RNA isolated from FFPE and other low quality clinical samples.


Cancer neoantigens

DIPNEOANTIGEN is a line of bioinformatics developed by DIPLOIDE for the accurate identification of cancer neoantigens with complete exome sequencing (WES) and complete transcriptome sequencing data for paired samples of normal tumors.


Microsatellite Instability (MSI)

MSI is the condition of genetic hypermutability. The FDA has approved the KEYTRUDA immunotherapies for the treatment of MSI-high solid tumors (MSI-H) and OPDIVO for the treatment of colorectal MS I-H cancers. We identified 19 of the 43 mononucleotide microsatellite loci covered by DIPRECISION for solid tumors, whose repeated lengths can reliably reflect the MSI status of tumor samples.


Mutation load TMB and bTMB

TMB represents the total number of mutations per coding area of a tumor genome.


It is usually calculated by sequencing the genome or exome of the tumor. The value of TMB correlates with the efficacy of some anti-PD1 / PD-L1 immunotherapies in certain types of tumors.

bottom of page